A Study of Petosemtamab With Pembrolizumab in People With Non-Small Cell Lung Cancer

Full Title

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Paul Paik’s office at 646-608-3759.

Protocol

26-128

Phase

Phase II (phase 2)

Disease Status

Relapsed or Refractory

Investigator

Paul K. Paik

Co-Investigators

Mark Awad

Diseases

Lung Cancer › Lung Cancer, Non-Small Cell

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07353957

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description